Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Study Comparing Symbicort 'as Needed' With Terbutaline 'as Needed' and With Pulmicort Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma

Trial Profile

A Clinical Study Comparing Symbicort 'as Needed' With Terbutaline 'as Needed' and With Pulmicort Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Budesonide; Terbutaline
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms SYGMA1
  • Sponsors AstraZeneca
  • Most Recent Events

    • 30 Sep 2019 According to an AstraZeneca Canada media release, based on positive results from the Phase III SYGMA 1 and 2 trials, the Health Canada has approved the expanded use of Symbicort Turbuhaler (budesonide/formoterol) for the treatment of mild persistent asthma in patients 12 years and older.Symbicort Turbuhaler is now approved as an anti-inflammatory reliever in Canada for use in mild persistent, moderate, or severe asthma patients.
    • 19 Sep 2018 Results of a post-hoc analysis presented at the 28th Annual Congress of the European Respiratory Society
    • 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top